Drug testing system with bio-artificial liver

a technology of artificial liver and testing system, which is applied in the direction of biomass after-treatment, specific use bioreactor/fermenter, instruments, etc., can solve the problems of liver damage, large development cost, and inability to manage the cost in the same way

Inactive Publication Date: 2005-06-16
HEPAHOPE
View PDF4 Cites 30 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A major portion of drug development costs is borne during the FDA approval process.
However, much of this cost cannot be managed in the same way that pre-clinical costs can.
Since the liver metabolizes most drugs, liver damage is of great concern.
However, these conventional tests have particular disadvantages, such as individual variation, high costs to use large animals, and loss of naturally existing characteristics of liver in situ.
However, with these models cell-to-cell connective interactions cannot be maintained for a desired length of time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug testing system with bio-artificial liver
  • Drug testing system with bio-artificial liver
  • Drug testing system with bio-artificial liver

Examples

Experimental program
Comparison scheme
Effect test

example 1

In Vitro Performance

[0035] The following example illustrates the in vitro performance of the system using liver slices and forms the model for the drug testing system of the present invention. The example here shows the efficiency of liver slices to metabolize ammonia and lidocaine in the presence of drug candidate HL100.

[0036] The liver converts ammonia to urea, which is excreted into the urine by the kidneys. In the presence of severe liver disease, ammonia accumulates in the blood because of both decreased blood clearance and decreased ability to form urea. Elevated ammonia levels can be toxic, especially to the brain, and play a role in the development of hepatic encephalopathy. Accordingly, measuring ammonia clearance can assess liver function. More specifically, measuring ammonia clearance provides an indication of the operability of the present invention to metabolize compounds that may or may not be harmful to the liver.

[0037] In addition, lidocaine is a drug that can be ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A drug testing system using a liver-slice culture apparatus. The apparatus has a chamber with plasma and gas valves, animal liver slices being positioned securely in the chamber so as to maximize the surface area of liver slices exposed to the culture medium. Plasma is supplied to the chamber so that it rises to contact the liver slices, and is alternately removed from contacting the liver slices. Gas is supplied to the top of the chamber. The system also includes a reservoir for containing media entering and exiting the chamber. Methods are provided for assessing the toxicity of a drug or drug candidate.

Description

BACKROUND OF THE INVENTION [0001] 1. Field of the Invention [0002] The invention relates to a drug testing system with a biological artificial liver and, more particularly, a bioreactor for evaluation, detection and testing of drug candidates, drugs and drug metabolites. [0003] 2. Discussion of Related Art [0004] In 2001, the average cost to develop a new drug exceeded $800 million, according to a study by the Tufts Center for the Study of Drug Development. Of this, approximately $16 million on average per company was used for pre-clinical research. Reduction of testing time and cost in drug development is therefore a critical factor to the survival of most pharmaceutical companies. In addition, since there is usually more than one company competing in the same drug arena, any competitive advantage would be welcome. A major portion of drug development costs is borne during the FDA approval process. However, much of this cost cannot be managed in the same way that pre-clinical costs ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A01N1/00C12M1/34C12M3/00C12M3/04C12N5/00C12Q1/00C12Q1/02G01N33/50
CPCG01N33/5082G01N33/5014C12M41/46
Inventor PARK, SUNG-SOO
Owner HEPAHOPE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap